0001104659-19-076941.txt : 20191230
0001104659-19-076941.hdr.sgml : 20191230
20191230214912
ACCESSION NUMBER: 0001104659-19-076941
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191230
FILED AS OF DATE: 20191230
DATE AS OF CHANGE: 20191230
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lam Thomas S.
CENTRAL INDEX KEY: 0001664499
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37392
FILM NUMBER: 191317872
MAIL ADDRESS:
STREET 1: 1668 GARFIELD AVE., 2ND FLOOR
CITY: ALHAMBRA
STATE: CA
ZIP: 91801
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Apollo Medical Holdings, Inc.
CENTRAL INDEX KEY: 0001083446
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MANAGEMENT CONSULTING SERVICES [8742]
IRS NUMBER: 870042699
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1668 S. GARFIELD AVENUE
STREET 2: 2ND FLOOR
CITY: ALHAMBRA
STATE: CA
ZIP: 91801
BUSINESS PHONE: (626) 282-0288
MAIL ADDRESS:
STREET 1: 1668 S. GARFIELD AVENUE
STREET 2: 2ND FLOOR
CITY: ALHAMBRA
STATE: CA
ZIP: 91801
FORMER COMPANY:
FORMER CONFORMED NAME: SICLONE INDUSTRIES INC
DATE OF NAME CHANGE: 19990413
4
1
tm1928380d3_4.xml
OWNERSHIP DOCUMENT
X0306
4
2019-12-30
0
0001083446
Apollo Medical Holdings, Inc.
AMEH
0001664499
Lam Thomas S.
1668 GARFIELD AVE., 2ND FLOOR
ALHAMBRA
CA
91801
1
1
0
0
President and Co-CEO
Common Stock
2019-12-30
4
A
0
61343
0
A
61343
D
Stock Option (right to buy)
18.65
2019-12-30
4
A
0
28046
0
A
2024-12-30
Common Stock
28046
28046
D
Restricted shares of Common Stock of Apollo Medical Holdings, Inc. (the "Company") granted under the Company's 2015 Equity Incentive Plan, subject to vesting one-third after year one (on December 30, 2020), one-third after year two (on December 30, 2021), and the final one-third after year three (on December 30, 2022).
Stock option to purchase the Company's Common Stock granted under the Company's 2015 Equity Incentive Plan, which stock option will vest and become exercisable one-third after year one (on December 30, 2020), one-third after year two (on December 30, 2021), and the final one-third after year three (on December 30, 2022), subject to expiration on the date that is five years from the date of grant (i.e., on December 30, 2024). The exercise price for each share subject to the stock option granted shall be set at the closing price of the Company's Common Stock on the date the grant was approved by the Company.
/s/ by Omar Dabuni as attorney-in-fact for Thomas Lam, M.D.
2019-12-30